Company Profile
Amgen Inc. Stock Price, News & Catalysts
- Ticker:
- AMGN
- Exchange:
- NASDAQ
- Sector:
- Generics, Biopharma, Oncology, Immunotherapy
- Location:
- Thousand Oaks, California
Stock performance
402.60 USD (-0.09%)
Close
Last updated: October 6, 2026
177B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, AMGN was little changed and closed at $402.60. No new same-company headline was identified in the current news window.
Company overview
Large-Cap Biotechnology Company
Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes medicines using human biology, advanced genetics, and protein engineering. Its portfolio spans general medicine, cardiovascular disease, rare disease, inflammation, hematology, and oncology, supported by large-scale biologic manufacturing and a growing small-molecule and RNA-based pipeline.
Obesity and General Medicine
The centerpiece of Amgen's metabolic pipeline is MariTide, an antibody-peptide conjugate that activates the GLP-1 receptor and antagonizes the GIP receptor. Its long-acting design supports monthly, every-eight-week, or quarterly dosing, and the broad MARITIME Phase 3 program covers obesity, type 2 diabetes, cardiovascular outcomes, heart failure, obstructive sleep apnea, treatment switching, and long-term weight maintenance.
Cardiovascular Portfolio
Amgen markets Repatha for LDL cholesterol reduction and is developing olpasiran, an siRNA designed to lower lipoprotein(a). The OCEAN(a) Phase 3 program includes secondary-prevention outcomes, primary-prevention outcomes, and coronary-plaque studies, giving the company multiple approaches to reducing atherosclerotic cardiovascular risk.
Rare Disease Franchise
The Horizon acquisition added UPLIZNA, TEPEZZA, KRYSTEXXA, and TAVNEOS, creating a sizable rare-disease business. Amgen is expanding these assets into new populations while developing dazodalibep, daxdilimab, and AMG 732 across Sjogren's disease, autoimmune disorders, and thyroid eye disease.
Inflammation and Autoimmune Disease
Amgen's inflammation portfolio includes TEZSPIRE, Otezla, and established biologics, with development extending into eosinophilic esophagitis, chronic obstructive pulmonary disease, rheumatoid arthritis, systemic lupus erythematosus, and autoimmune kidney disease. Programs such as blinatumomab and inebilizumab also apply B-cell depletion and T-cell engagement technologies outside oncology.
Oncology and BiTE Platform
The oncology business includes BLINCYTO and IMDELLTRA, both built on Amgen's bispecific T-cell engager platform. IMDELLTRA is being studied across extensive-stage and limited-stage small-cell lung cancer in multiple combinations and dosing formats, while BLINCYTO development continues across leukemia settings and selected autoimmune diseases.
Future catalysts
- Initiation of three Phase 3 MariTide studies in people with type 2 diabetes during 2026.
- Completion of two Phase 3 dazodalibep studies in Sjogren's disease in the second half of 2026.
- Completion of the Phase 3 TEZSPIRE study in eosinophilic esophagitis in the second half of 2026.
- Initiation of a Phase 3 UPLIZNA study in chronic inflammatory demyelinating polyneuropathy between the second half of 2026 and the first half of 2027.
Recent news
- 01
- 02
Management commentary keeps pipeline priorities in focus
- 03
Investors watch oncology and cardiometabolic launch cadence
- 04
Regulatory calendar keeps Amgen in the spotlight
- 05
Pipeline updates reinforce the commercial-stage narrative
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amgen Inc. (AMGN)?
Amgen Inc. (AMGN) most recently closed at 402.60 USD, a -0.09% move versus the previous session.
What is the market cap of Amgen Inc. (AMGN)?
Amgen Inc. currently has a market capitalization of 177B USD on BioPharmSignal.
What does Amgen Inc. do?
Large-Cap Biotechnology Company Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes medicines using human biology, advanced genetics, and protein engineering. Its portfolio spans general medicine, cardiovascular disease, rare disease, inflammation, hematology, and oncology, supported by large-scale biologic...
On which exchange is AMGN stock listed?
Amgen Inc. (AMGN) is associated with NASDAQ, Thousand Oaks, California, Generics, Biopharma, Oncology, Immunotherapy.
What is GLP-1?
Obesity and General Medicine The centerpiece of Amgen's metabolic pipeline is MariTide, an antibody-peptide conjugate that activates the GLP-1 receptor and antagonizes the GIP receptor.
Which conditions is Amgen Inc. targeting with GLP-1?
Amgen Inc. is associated with oncology, cancer therapeutics, inflammatory disease based on its company overview and current catalyst commentary.
How does Amgen Inc. describe recent progress with GLP-1?
Initiation of three Phase 3 MariTide studies in people with type 2 diabetes during 2026. Completion of two Phase 3 dazodalibep studies in Sjogren's disease in the second half of 2026. Completion of the Phase 3 TEZSPIRE study in eosinophilic esophagitis in the second half of 2026. Initiation of a Phase 3 UPLIZNA study in chronic inflammatory demyelinating...
What is daxdilimab?
Amgen is expanding these assets into new populations while developing dazodalibep, daxdilimab, and AMG 732 across Sjogren's disease, autoimmune disorders, and thyroid eye disease.